Johnson & Johnson said on Monday, November 16, 2026 that it has signed a definitive agreement to acquire Ollin Biosciences, a clinical-stage biopharmaceutical company focused on serious eye diseases, for $2.2 billion upfront, according to the company's release carried by Business Wire.
What happened
Johnson & Johnson announced in a release distributed by Business Wire that it will acquire Ollin Biosciences, a clinical-stage biopharmaceutical company developing treatments for serious eye diseases. The company said the deal includes $2.2 billion paid upfront, with further regulatory and commercial milestone payments possible depending on outcomes. Business Wire's release noted the acquisition centers on a late-stage bispecific antibody, a lab-made protein that can bind two different targets at once, that Johnson & Johnson described as having best-in-class potential in ophthalmology, the branch of medicine focused on eye care.
How the stock has moved
Johnson & Johnson shares traded at $288.85 in pre-market trading, before the regular session opens, up 1.08% from Friday's close of $285.75. The move matches the stock's gain since the deal was first reported.
| Measure | Value |
|---|---|
| Price, pre-market trading | $288.85 |
| Since the close before the first report (Friday, November 13, 2026) | +1.08% |
| Change from the close on Friday, November 13, 2026 | +1.08% |
| Market value at the close on Friday, November 13, 2026 | $687.89 billion |
Source: Stock quote; the close before the first report from our saved closes · as of November 16, 2026 at 8:18 AM ET · Shows what the stock did after the news was first reported, not why.
Its suppliers and customers
Among suppliers and customers named in company filings, Microsoft and Martin Marietta Materials were trading higher outside the regular session, while Citigroup was lower. Intra-Cellular Therapies, Shockwave and Halda Therapeutics, also named in filings, showed no trades outside the regular session.
| Company | Role | Stock | Since last close |
|---|---|---|---|
| Microsoft | Supplier | MSFT | +0.16% |
| Citigroup | Supplier | C | -0.62% |
| Martin Marietta Materials | Supplier | MLM | +0.94% |
| Intra-Cellular Therapies | Customer | Not listed | — |
| Shockwave | Customer | Not listed | — |
| Intra-Cellular Therapies | Supplier | Not listed | — |
| Halda Therapeutics | Supplier | Not listed | — |
Source: Relationships named in company filings (Earnings call transcript; SEC 10-K annual report); stock quotes · as of November 16, 2026 at 8:18 AM ET · A supplier or customer moving the same day is not evidence that one move caused the other.